Clinical Trials

At the Gerald J. Glasser Brain Tumor Center, a dynamic clinical trial research program is dedicated to bringing cutting-edge treatments and novel therapies to our patients. From advancements in immunotherapy and chemotherapy to precision treatments tailored to individual genetic profiles, we strive to offer the most innovative options available.

Brain Metastases

  • Genetic-Guided Treatment for Brain Metastases

    This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Learn more about this trial

Glioblastomas

  • For Newly Diagnosed Patients with Glioblastoma Multiform (GBM)

    Phase IIb RESTORE Trial
    This phase II trial examines whether increasing oxygen delivery to hypoxic glioblastoma tissue via NanO2 will boost the effectiveness of frontline treatment with both radiation therapy and chemotherapy.
    Learn more about this trial

  • For Newly Diagnosed Patients

    Immunotherapy and Radiation Therapy for Newly Diagnosed Glioblastoma
    Designed for patients who are newly diagnosed with MGMT-unmethylated glioblastoma, this phase II/III study tests the use of immunotherapy drugs ipilimumab and nivolumab – which may help the body’s immune system attack cancer cells – with radiation therapy.
    Learn more about this trial

  • For Patients with Recurrent Glioblastoma

    Immunotherapy for Recurrent Glioblastoma
    This phase II study examines immunotherapy drugs Tocilizumab and Atezolizumab and stereotactic radiation therapy in patients with glioblastoma that has recurred after initial treatment. These immunotherapy medications with monoclonal antibodies may help the body’s immune system attack cancerous cells and may interfere with tumor cells’ ability to grow and spread.
    Learn more about this trial

Gliomas

  • For Newly Diagnosed Patients

    ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy

    This Phase 3 study is to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

    Learn more about this trial

  • For Patients with Recurrent High-Grade Glioma

    The objective of this study is to evaluate the efficacy of plixorafenib in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation.
    Learn more about this trial

  • For Patients with Recurrent or Progressive grade 3 or 4 Gliomas

    This multi-site, Phase 1/2a clinical trial is an open label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma or patients with progressed or recurrent Grade III glioma.
    Learn more about this trial

  • For Patients with H3-K27M-mutant and/or Midline Gliomas

    This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
    Learn more about this trial

Meningiomas

  • Inhibitor Drug Therapy for Progressive Meningiomas

    Designed for patients with meningiomas that are growing, spreading or getting worse, this phase II trial studies the efficacy of inhibitor drugs that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Request a Consultation

Personalized treatment plans from start to finish.

Second Opinion

Get the peace of mind that comes with knowing your options.

Contact Us

Your feedback and questions are important to us.